A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Clinical trial NCT01970865 · COMPLETED

Trial details

NCT number: NCT01970865
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Start date: 2014-01-08
Primary completion: 2017-03-15
Enrollment: 364

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.